glaxosmithkline

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Initial and secondary public offerings enticed insiders to come out and buy shares this past week. Besides IPOs, biotechs and special purpose acquisition companies are well...

Benzinga has examined the prospects for many investor favorite stocks over the past week. The past week's bullish calls included the electric vehicle leader and a prominent IPO. Short sellers were behind some of the bearish calls seen during the week. The Dow Jones industrial average crossed...

This weekend's Barron's cover offers a low-risk strategy for investors optimistic about an ecomomic recovery. Other featured articles discuss what a COVID-19 vaccine would mean for the stock market and how it could shake up the pharmaceutical industry. Also, the prospects for semiconductor...

Insider buying can be an encouraging signal for potential investors. Insiders at biotechs took advantage of initial and secondary public offerings. Notable insider purchases were also seen at some industrial companies. Conventional wisdom says that insiders and 10% owners really only buy shares...

This weekend's Barron's examines why things may be looking up for one big oil company. Other featured articles offer the prospects for a big drug maker facing stiff competition and a glassmaker that may see growing demand. Also, the first FANG component to offer a dividend and...

Undaunted by two earlier FDA snubs, Dynavax Technologies Corporation (NASDAQ: DVAX) is trying again with its hepatitis B vaccine, Heplisav. Will it successfully scale the hurdle the third time? Investors are waiting for an answer, as the FDA is set to give its verdict on the Biologic License...

The biotech space can be an investor's delight, fetching staggering returns, while at the same time taking them through the throes of despair if bets go wrong — all courtesy of make-or-break events. In September, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has lost 0.44...

The cover story in this weekend's Barron's features the launch of the new Barron's Alternatives Monthly. This issue also includes picks from the Barron's Art of Successful Investing conference. The prospects for Sherwin-Williams, GlaxoSmithKline, Barnes & Noble...

GlaxoSmithKline plc (ADR) (NYSE: GSK) is near its 52-week lows after having fallen 6.2 percent this year. Following topline results from GlaxoSmithKline's SUMMIT study, Goldman Sach's Keyur Parekh called the results an "unexpected disappointment." For GSK financially, the results were only a "...

U.S. stocks declined as geopolitical concerns outweighed an improved economic read on second-quarter growth. Ukraine's President stated that Russian troops had crossed in to Ukraine territory and were fighting alongside Russian supported separatists. Markets initially traded lower on the...

U.S. stocks were little changed ahead of the Federal Reserve's policy announcement due out on Wednesday. The Federal Reserve will conclude a two-day session, with the central bank likely to announce further cuts to its monthly asset purchases. In economic news, June home sales declined in...

U.S. stocks sold off after news reports began to surface that a Malaysian Airlines jet has crashed in Ukraine. While details have yet to be confirmed, a Ukraine minister claimed that the plane, which carried nearly 300 people, was shot down by rebels. Also not helping the market sentiment...

U.S. stocks rose as investors cheered recent earning reports and a positive home sales data for March. A $45 billion M&A offer also contributed to Tuesday's buying action as investors could be excited and motivated to buy stocks ahead of a few rough weeks of bearish activity. The S&P...